Who is sponsoring NCT04621578?

NCT04621578 is sponsored by Peking University People's Hospital.

What drugs are being tested in NCT04621578?

Interventions in NCT04621578: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China).

What condition does NCT04621578 study?

NCT04621578 studies Transcutaneous Electrical Acupoint Stimulation, Hemifacial Spasm, Dizziness.

Is NCT04621578 still recruiting?

NCT04621578 is currently completed. Last updated 1 June 2022.

Last reviewed 2022-06-01 · How we verify

NCT04621578

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcutaneous Electrical Acupoint Stimulation on Postoperative Dizziness in Hemifacial Spasm Patients

Completed NA Last updated 1 June 2022

What this trial tests

NA trial testing HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China) in Transcutaneous Electrical Acupoint Stimulation in 86 participants. Completed in 30 July 2021.

Timeline

6 December 2020

Primary endpoint
25 June 2021

30 July 2021

Quick facts

Lead sponsor	Peking University People's Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	86
Start date	6 December 2020
Primary completion	25 June 2021
Estimated completion	30 July 2021
Sites	1 location across China

Drugs / interventions tested

HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)

Conditions studied

Transcutaneous Electrical Acupoint Stimulation — all drugs for Transcutaneous Electrical Acupoint Stimulation →
Hemifacial Spasm — all drugs for Hemifacial Spasm →
Dizziness — all drugs for Dizziness →

Sponsor

Peking University People's Hospital

Who can join

Adults 18 to 70, any sex, with Transcutaneous Electrical Acupoint Stimulation or Hemifacial Spasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe the prevention and treatment effect of transcutaneous electrical acupoint stimulation (TEAS) on postoperative dizziness in patients with hemifacial spasm undergoing microvascular decompression surgery, and its possible mechanisms.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Peking University People's Hospital trials

Trials by the same sponsor.

NCT07535645 — Baricitinib for Post-HSCT Persistent Thrombocytopenia · Phase 1, PHASE2 · not yet recruiting
NCT07516002 — Immunoglobulin Efficacy and Immune Profiling in Antibody Immunodeficiency · not yet recruiting
NCT07294339 — A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positiv · NA · not yet recruiting
NCT07500441 — Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04621578 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University People's Hospital
Last refreshed: 1 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04621578.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing